Press Releases

10.25.2018

CANCER THERAPEUTICS CRC SIGNS AGREEMENT TO ENABLE PFIZER TO DEVELOP NOVEL CANCER DRUGS

10.23.2018

Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients

10.23.2018

Bain Capital and Pfizer Create Cerevel Therapeutics, New CNS Company

10.20.2018

Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCE® (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer

10.16.2018

U.S. FDA Approves TALZENNA® (talazoparib)

10.09.2018

Pfizer Announces Executive Leadership Team

10.04.2018

Pfizer to Award More Than $3 Million in Grants to Further Breast Cancer Research

10.01.2018

Pfizer Announces CEO Succession

09.27.2018

U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer

09.27.2018

Pfizer Declares 34-Cent Fourth-Quarter 2018 Dividend

09.20.2018

Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older

09.18.2018

Pfizer Invites Public to View and Listen to Webcast of October 30 Conference Call with Analysts